News
2 Jul 2026
Glenmark Advances Multi-Country Phase 3 Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer
Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the advancement of its multi-country Phase 3…
